ATS 2018 International Conference - Mobile

A Randomized, Placebo-Controlled, Double Blind Phase Iia Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 12 Weeks of Treatment of an Autotaxin Inhibitor (GLPG1690) in Individuals with Idiopathic Pulmonary Fibrosis (FLORA Trial)

Location: 6A

Session Type: Mini Symposium

Sunday

May

20

2:45 PM

3:00 PM

Speaker(s)/Author(s)

Fieuw Ann

MD
Galapagos NV

Liesbeth Fagard

PhD
Galapagos;Galapagos NV

Julie Desrivot

PhD
Galapagos;Galapagos SASU

Sonia Dupont

PhD
Galapagos;Galapagos SASU

Toby M. Maher

MD, MSc, PhD, FRCP
Imperial College;Imperial College London;Imperial College, London;National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Hare;Royal Brompton and Harefield NHS

Wim Wuyts

MD, PhD
KU Leuven;University Hospitals Leuven;University of Leuven

Lisa Allamassey

PhD
Galapagos;Galapagos NV

Olivier Van de Steen

MD
Galapagos

Elisabeth van der Aar

PhD
Galapagos;Galapagos NV

View Abstract

A Randomized, Placebo-Controlled, Double Blind Phase Iia Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 12 Weeks of Treatment of an Autotaxin Inhibitor (GLPG1690) in Individuals with Idiopathic .

Parent Sessions

A93 - ILD: CLINICAL TRIALS
05-20-2018 2:15 PM - 4:15 PM